Legal Representation
Attorney
Tara Sliva
USPTO Deadlines
Next Renewal Deadline
238 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-03-03)
Due Date
March 03, 2026
Grace Period Ends
September 03, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
20 eventsDate | Code | Type | Description |
---|---|---|---|
Mar 3, 2025 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
Aug 18, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
Aug 18, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
Aug 18, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
Mar 3, 2020 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
Dec 17, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Dec 17, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION |
Nov 27, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Nov 7, 2019 | ALIE | A | ASSIGNED TO LIE |
Nov 4, 2019 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
Oct 31, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
Oct 30, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Oct 30, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Sep 5, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Sep 5, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED |
Sep 5, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN |
Sep 5, 2019 | DOCK | D | ASSIGNED TO EXAMINER |
Aug 1, 2019 | MDSM | E | NOTICE OF DESIGN SEARCH CODE E-MAILED |
Jul 31, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Jul 26, 2019 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 001
Biochemicals and organic chemicals used as enzyme substrates, enzyme inducers, namely, aminoglutethimides, carbamazepines, griseofulvins, and primidones, enzyme inactivators, or cultural medium additives for use in the field of microbiology and molecular biology; biochemical and organic chemical reagents for clinical diagnostic laboratory use; biochemical and organic chemicals for use in the manufacture of pharmaceuticals and cosmetics; Chemical reagents for medical research use in the field of immunology; Chemical reagents for medical laboratory analysis purposes, namely, for use as a routine medical supplement to blood culture media in vitro to inhibit blood coagulation and to improve the detection limits for individual microorganisms
First Use Anywhere:
Jul 1, 2019
First Use in Commerce:
Jul 1, 2019
Class 005
Medicinal preparations, namely, photosensitizing agents used as a dermatologic drug for the treatment of skin cancer by phototherapy; Chemical reagents for medical or veterinarian use; Chemical reagents for use as a culture media for cultures of microorganisms for medical use, namely, for the isolation and identification of the bacteria strain Escherichia coli O157:H7; Chemical preparations for medical purposes, namely, for Cholesterol testing to prevent possible consequences of Hypercholesterolemia such as atherosclerosis, coronary heart disease and other forms of cardiovascular diseases; Chemical preparations for medical purposes, namely, for novel enzyme responsive inhibitors that allow for modifications of the composition of microbial communities; Organic chemical preparations for medical purposes, namely, immunomodulators with anti-inflammatory properties; Organic chemical preparations and enzymes for medical laboratory analysis purposes, namely, for medical detection, identification and quantification of strains of pathogenic bacteria; Chemical preparations for medical laboratory analysis purposes, namely, for medical immunological and microbiological blood testing; Chemical preparations for medical laboratory analysis purposes, namely, for medical detection of pathogenic bacteria, namely, various strains of Listeria, Clostridium, Bacillus and Staphylococcus; Chemical preparations for medical laboratory analysis purposes, namely, for the medical detection and quantification of bacteria strains of Escherichia coli; Medical preparations for the diagnosis of Staphylococus aureus, in particular for Methicillin-resistant Staphylococcus aureus (MRSA)
First Use Anywhere:
Jul 1, 2019
First Use in Commerce:
Jul 1, 2019
Additional Information
Design Mark
The mark consists of the stylized word "BIOSYNTH" in blue on top of a blue rectangle with the stylized word "CARBOSYNTH" in white inside the rectangle with a grey line underneath the rectangle.
Color Claim
The color(s) blue, grey and white is/are claimed as a feature of the mark.
Pseudo Mark
BIO SYNTH CARBO SYNTH
Classification
International Classes
001
005